Literature DB >> 23024375

Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization.

Virginia Tirino1, Vincenzo Desiderio, Francesca Paino, Alfredo De Rosa, Federica Papaccio, Marcella La Noce, Luigi Laino, Francesco De Francesco, Gianpaolo Papaccio.   

Abstract

Primary tumors are responsible for 10% of cancer deaths. In most cases, the main cause of mortality is the formation of metastases. Accumulating evidence suggests that a subpopulation of tumor cells with distinct stem-like properties is responsible for tumor initiation, invasive growth, and metastasis formation. This population is defined as cancer stem cells (CSCs). Existing therapies have enhanced the length of survival after diagnosis of cancer but have completely failed in terms of recovery. CSCs appear to be resistant to chemotherapy, may remain quiescent for extended periods, and have affinity for hypoxic environments. The CSCs can be identified and isolated by different methodologies, including isolation by CSC-specific cell surface marker expression, detection of side population phenotype by Hoechst 33342 exclusion, assessment of their ability to grow as floating spheres, and aldehyde dehydrogenase (ALDH) activity assay. None of the methods mentioned are exclusively used to isolate the solid tumor CSCs, highlighting the imperative to delineate more specific markers or to use combinatorial markers and methodologies. This review provides an overview of the main characteristics and approaches used to identify, isolate, and characterize CSCs from solid tumors.

Entities:  

Mesh:

Year:  2012        PMID: 23024375     DOI: 10.1096/fj.12-218222

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  147 in total

1.  Therapeutic vaccination based on side population cells transduced by the granulocyte-macrophage colony-stimulating factor gene elicits potent antitumor immunity.

Authors:  C Sakamoto; H Kohara; H Inoue; M Narusawa; Y Ogawa; L Hirose-Yotsuya; S Miyamoto; Y Matsumura; K Yamada; A Takahashi; K Tani
Journal:  Cancer Gene Ther       Date:  2017-01-13       Impact factor: 5.987

2.  Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells.

Authors:  Amit Kumar Srivastava; Chunhua Han; Ran Zhao; Tiantian Cui; Yuntao Dai; Charlene Mao; Weiqiang Zhao; Xiaoli Zhang; Jianhua Yu; Qi-En Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

3.  NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells.

Authors:  Filippos Kottakis; Parthena Foltopoulou; Ioannis Sanidas; Patricia Keller; Ania Wronski; Benjamin T Dake; Scott A Ezell; Zhu Shen; Stephen P Naber; Philip W Hinds; Elizabeth McNiel; Charlotte Kuperwasser; Philip N Tsichlis
Journal:  Cancer Res       Date:  2014-05-22       Impact factor: 12.701

Review 4.  Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.

Authors:  Bert Gold; Milena Cankovic; Larissa V Furtado; Frederick Meier; Christopher D Gocke
Journal:  J Mol Diagn       Date:  2015-05       Impact factor: 5.568

5.  Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/β-catenin signal pathway.

Authors:  Gaochao Hou; Xiang Yuan; Yi Li; Gaoyu Hou; Xianli Liu
Journal:  Invest New Drugs       Date:  2019-05-17       Impact factor: 3.850

6.  Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas.

Authors:  Elham Kalantari; Mojgan Asgari; Seyedehmoozhan Nikpanah; Naghme Salarieh; Mohammad Hossein Asadi Lari; Zahra Madjd
Journal:  Pathol Oncol Res       Date:  2017-01-12       Impact factor: 3.201

Review 7.  Lung cancer and β-glucans: review of potential therapeutic applications.

Authors:  Raheleh Roudi; Shahla Roudbar Mohammadi; Maryam Roudbary; Monireh Mohsenzadegan
Journal:  Invest New Drugs       Date:  2017-03-16       Impact factor: 3.850

Review 8.  Prognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysis.

Authors:  Quan Zhou; Aihua Chen; Huamei Song; Jing Tao; Huaijie Yang; Manzhen Zuo
Journal:  Int J Clin Exp Med       Date:  2015-03-15

9.  Cancer stem cells as a potential therapeutic target in thyroid carcinoma.

Authors:  Luisa Vicari; Cristina Colarossi; Dario Giuffrida; Ruggero De Maria; Lorenzo Memeo
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

10.  DDB2 suppresses tumorigenicity by limiting the cancer stem cell population in ovarian cancer.

Authors:  Chunhua Han; Ran Zhao; Xingluo Liu; Amit Srivastava; Li Gong; Hsiaoyin Mao; Meihua Qu; Weiqiang Zhao; Jianhua Yu; Qi-En Wang
Journal:  Mol Cancer Res       Date:  2014-02-26       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.